Pancreatic ductal adenocarcinoma

Researchers test whether a short course of targeted radiation followed by the immunotherapy drug adebrelimab and NALIRIFOX chemotherapy can shrink locally advanced pancreatic cancer enough to allow surgery. The trial enrolls 36 adults with previously untreated pancreatic ductal a…

Researchers are testing a new immunotherapy called Lm-LLO-TT in adults with advanced pancreatic ductal adenocarcinoma that has already been treated with chemotherapy. Lm-LLO-TT uses a weakened form of Listeria bacteria engineered to carry a tetanus toxoid antigen, aiming to spark…

Researchers at the University of Oklahoma are testing whether adding pentamidine, an antiparasitic drug, to standard modified FOLFIRINOX chemotherapy is safe and helps shrink tumors in people with advanced or metastatic pancreatic cancer. Up to 30 adults with confirmed locally ad…

Researchers are testing whether adding two oral drugs, avutometinib and defactinib, to standard chemotherapy (mFOLFIRINOX) is safe and can slow or shrink pancreatic ductal adenocarcinoma. The trial has two parts: one for people whose cancer has spread, and one for people whose ca…

Researchers are testing whether combining retlirafusp alfa, famitinib, and AG chemotherapy (nab-paclitaxel plus gemcitabine) can slow cancer growth in people with unresectable pancreatic cancer. The trial enrolls about 88 adults with locally advanced or metastatic pancreatic duct…

This early-stage trial tests an investigational drug called ABBV-253 in adults with advanced solid tumors, including lung, colorectal, and pancreatic cancers. The study aims to find safe doses and see whether the drug can shrink tumors. Participants receive the drug by infusion, …

This phase III trial tests an experimental drug called YL201 against standard chemotherapy in people with metastatic pancreatic cancer that has progressed after gemcitabine-based treatment. YL201 is designed to deliver a toxin directly to cancer cells that carry a specific marker…

This trial tests whether adding an experimental immunotherapy (SHR-1701) and a targeted drug (apatinib) to standard chemotherapy (gemcitabine and nab-paclitaxel) can help people with advanced pancreatic cancer. The study enrolls adults aged 18 to 75 who have not yet received trea…

This trial compares two surgical approaches for people with pancreatic cancer in the left side of the pancreas. One method removes the spleen along with the tumor, which is standard practice. The other preserves the spleen, potentially reducing complications and avoiding lifelong…

This early-phase trial will test a combination of two drugs—JDB153 (taken as a pill) and serplulimab (given by IV)—in 10 people with advanced pancreatic cancer that has not responded to standard treatments. The main goals are to check safety and see if the drugs can shrink tumors…

This phase II trial tests whether choosing chemotherapy based on a specific gene mutation (SMAD4) can improve outcomes for people with pancreatic cancer that is or may be surgically removable. The SMAD4 gene normally acts as a brake on tumor growth, but when it's mutated, tumors …

This phase 2 trial is testing a novel combination for people with metastatic pancreatic cancer that has progressed after standard first-line chemotherapy. The approach combines a device that alternately freezes and heats the tumor (multimodal thermal therapy) with a personalized …

This early-stage trial is testing an experimental treatment called the IKS04 regimen in people with advanced cancers of the digestive system, including colorectal, stomach, pancreatic, and bile duct cancers. The regimen combines a targeted antibody-drug conjugate with an addition…

This phase II trial is testing whether adding an immunotherapy drug (serplulimab) and a targeted antibody (bevacizumab) to standard chemotherapy can help people with metastatic pancreatic cancer that has progressed after initial treatment. The study enrolls about 34 adults whose …

This early-phase trial tests an experimental drug called XNW28012 in people with metastatic pancreatic cancer whose disease has worsened after at least one prior treatment. XNW28012 is an antibody-drug conjugate designed to seek out a protein called tissue factor on cancer cells …

This trial investigates whether raising the body's core temperature to 41.5°C for 4 hours, called whole-body hyperthermia, can improve outcomes when added to standard chemotherapy for people with metastatic pancreatic cancer that has progressed after initial treatment. The study …

This study tests an experimental drug called HSK41959, taken as a tablet, in combination with standard cancer treatments for people with advanced solid tumors that lack a gene called MTAP. The trial includes patients with non-small cell lung cancer, pancreatic cancer, and other a…

This study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and…

This phase 2 trial tests the drug inavolisib in people with pancreatic ductal adenocarcinoma whose cancer has worsened after prior chemotherapy. The study aims to see if inavolisib can shrink tumors or slow disease progression. Participants take inavolisib daily by mouth, and the…

This phase 2 trial tests whether adding the experimental drug HRS-4642 to standard chemotherapy, with or without the immunotherapy adebrelimab, can shrink pancreatic tumors before surgery. The study enrolls adults aged 18-70 with pancreatic ductal adenocarcinoma who have at least…

This phase 2 trial tests a new treatment approach for people with locally advanced pancreatic cancer that cannot be removed by surgery. Participants receive targeted radiation therapy followed by a combination of two immunotherapy drugs (ipilimumab N01 and sintilimab) plus standa…

This study tests a new drug called becotatugvedotin combined with the chemotherapy gemcitabine for people with advanced pancreatic cancer that has not responded to first-line treatment. The trial has two phases: first, to find the safest dose of the new drug, and second, to see h…

This study tests a new drug called samuraciclib added to standard chemotherapy for people with a specific type of advanced pancreatic cancer (basal-like). The goal is to find the safest dose and see if the combination helps shrink tumors or slow the cancer. About 67 adults with n…

This early-stage trial tests whether combining two drugs—selumetinib and DS-8201a—can safely shrink or control advanced pancreatic cancer that has a specific genetic change (KRAS mutation) and a protein called HER2. About 31 adults with cancer that cannot be removed by surgery or…

This early-phase trial tests a new peptide nanovaccine (ONVAX-01) together with an anti-PD-1 antibody and standard chemotherapy in 9 people with advanced pancreatic cancer that has worsened after prior treatment. The main goals are to see if the combination is safe and whether it…

This phase II trial tests whether a genetic signature can personalize chemotherapy for people with borderline resectable pancreatic cancer. About 110 participants will receive either a standard chemo regimen or one chosen based on their tumor's genetic profile. The goal is to see…

This study tests a new drug (GV20-0251) combined with an immunotherapy (anti-PD-1) in people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. About 227 adults with various cancers, including lung, breast, and colorectal, will participa…

This early-stage study tests a new tablet, LT-010391, in people with advanced solid tumors (lung, colon, or pancreatic cancer) that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 198 participants who have tried o…

This study tests a drug called lorigerlimab in people with advanced pancreatic cancer that has a specific genetic makeup (BRCA, PALB2, or RAD51C/D mutations). The goal is to see if the drug can shrink tumors. About 40 adults will take part, and the study is not yet recruiting.

This early-phase study tests a new drug combination (L19IL2 plus ruxolitinib) in people with advanced kidney, pancreatic, or colorectal cancers that have stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. About 96 partici…

This phase II trial tests a drug called sacituzumab tirumotecan in 30 people with advanced pancreatic cancer that has worsened after at least one prior treatment. The drug is given by IV every two weeks. The main goal is to see if it can shrink tumors, and researchers will also t…

This early-stage trial tests a new type of cell therapy for people with advanced pancreatic cancer that has stopped responding to chemotherapy. The treatment uses a patient's own immune cells, called macrophages, that are engineered in a lab to recognize and attack cancer cells c…

This early-phase trial tests whether adding the experimental drug NRT6008 to standard chemotherapy is safe and helps shrink tumors in people with advanced pancreatic cancer that cannot be removed by surgery. About 10 adults aged 18 to 85 with this condition will receive the combi…

This study tests whether changing the order of steps during a Whipple surgery for pancreatic head cancer can help surgeons remove the tumor more completely and lower the chance of cancer coming back. About 150 adults with operable pancreatic cancer will be randomly assigned to ei…

This study tests a device called ONCObind that filters cancer cells from the blood of people with advanced pancreatic or colorectal cancer that has not responded to standard treatments. About 120 adults will receive the filtering procedure multiple times to see if it is safe and …

This early-phase trial is testing a new chemotherapy drug called RP-001 in 66 adults with advanced solid tumors, including colorectal and pancreatic cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. It is an open-label study, …

This early-phase trial tests whether delivering the chemotherapy drug gemcitabine directly into the artery feeding the tumor can improve surgical outcomes for people with borderline resectable pancreatic cancer. Ten participants will receive standard chemo and radiation, followed…

This early-phase trial tests whether adding the migraine drug rimegepant to standard chemotherapy can help people with metastatic pancreatic cancer. About 30 adults who have not had prior treatment will receive the combination. Researchers will track how long the cancer stays und…

This Phase III trial is testing whether adding the experimental drug chiauranib and an immunotherapy (toripalimab) to standard chemotherapy can help people with metastatic pancreatic cancer live longer. About 558 participants will be randomly assigned to receive either the full c…

This early-phase trial will test whether adding the study drug NP137 to standard chemotherapy (FOLFIRINOX) can change the behavior of pancreatic cancer cells before and after surgery. About 25 people with resectable pancreatic cancer will receive the combination, and researchers …

This Phase 3 trial tests whether adding the experimental antibody FG-M108 to standard chemotherapy (gemcitabine and nab-paclitaxel) helps people with advanced pancreatic cancer live longer. About 524 participants with Claudin18.2-positive tumors will be randomly assigned to recei…

This early-stage trial tests whether adding ATRA, SDK002, and an immunotherapy drug to standard chemotherapy is safe for people with advanced pancreatic cancer that cannot be removed by surgery. Ten participants will receive all five drugs together. The study will also track how …

This Phase III trial tests whether adding targeted radiation and an immunotherapy drug (serplulimab) to standard chemotherapy can help people with advanced pancreatic cancer live longer. About 198 participants who have not had prior treatment will be randomly assigned to receive …

This study tests a new first-line treatment for people with pancreatic cancer that has spread to the liver. The treatment combines chemotherapy delivered directly to the liver with two immunotherapy drugs. The goal is to see if this approach can slow or stop cancer growth. The st…

This early-phase study tests a new approach for people with pancreatic cancer that has spread to the liver and who have already tried standard chemotherapy. The treatment combines standard chemotherapy drugs with a special ultrasound technique that uses tiny bubbles to help deliv…

This study tests a new drug called HLX43 in 100 adults with advanced pancreatic cancer that has not responded to other treatments. The drug is designed to target and attack cancer cells while limiting harm to healthy cells. The goal is to see if it can shrink tumors or slow the d…

This study tests a new drug called TYK-01054 for people with advanced solid tumors that have not responded to standard treatments. The drug is taken as a capsule and works by blocking a protein (TEAD) involved in cancer growth. The trial will check safety, find the best dose, and…

This phase 2 trial tests whether adding nimotuzumab, a targeted antibody, to standard chemotherapy can help people with high-risk pancreatic cancer that can still be surgically removed. About 156 participants will receive either the drug combo or a placebo before and after surger…

This early-phase trial tests two drugs (cosibelimab and balixafortide) together in people with advanced pancreatic cancer that has stopped responding to standard chemotherapy. The main goal is to find the safest dose and check for side effects. About 24 adults will take part in t…

This Phase 2 trial will test an experimental drug called SSGJ-706 combined with standard chemotherapy (and sometimes another drug, bevacizumab) in 300 people with advanced gastrointestinal cancers that cannot be surgically removed. The goal is to see if the combination is safe an…

This study tests an experimental oral drug called GFH276 in people with advanced solid tumors that have RAS mutations, including pancreatic, lung, and colorectal cancers. The trial has two parts: Phase 1 finds the safest dose, and Phase 2 checks if the drug shrinks tumors. About …

This early-phase trial tests a new treatment called CD318-CAR-T cells for people with advanced pancreatic cancer that has worsened after standard therapy. The therapy uses a patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The study ai…

This registry study follows 400 people at increased risk for pancreatic ductal adenocarcinoma who receive PancreaSure, a blood test designed to detect early-stage disease. Researchers track whether the test results lead doctors to change surveillance plans, such as scheduling mor…

This trial is testing two new imaging tracers, called CM500, to see if they can help detect solid tumors anywhere in the body. The tracers are given by injection and then used with PET scans to create detailed images. The study includes healthy volunteers and people with various …

This study aims to find molecular clues that could predict whether certain pancreatic growths will turn into cancer. Researchers will analyze tissue from patients having pancreatic surgery, using advanced genetic and protein tests on both the original tissue and lab-grown 3D cell…

Researchers at MD Anderson Cancer Center are studying whether routine electronic symptom monitoring improves quality of life and care experience for patients with pancreatic adenocarcinoma receiving chemotherapy or radiation before surgery. About 200 adults with operable or local…

Researchers are testing whether a digital nutrition app called STRONG, paired with remote dietitian counseling, is practical and helpful for adults with pancreatic ductal adenocarcinoma who are starting chemotherapy or radiation. About 80 participants join the study and are assig…

Researchers are testing whether personalised nutritional care from a trained dietitian improves quality of life for people aged 65 and older with pancreatic ductal adenocarcinoma. About 250 participants will be randomly assigned to either six months of individualised nutrition su…

This early study tests whether selpercatinib, a drug already used for certain cancers, can help with cachexia (severe weight loss and appetite loss) in people with advanced lung, colon, or pancreatic cancer. Seven participants will take the drug twice daily for 12 weeks, with reg…

This observational study tests whether artificial intelligence can predict how well pancreatic cancer responds to chemotherapy and how the disease may progress. Researchers will analyze data from 700 patients, including endoscopic ultrasound images, CT/MRI scans, lab results, and…

This study will watch how doctors use a special camera (endoscopic ultrasound) to diagnose suspected pancreatic or bile duct diseases in 2500 adults across Lombardy, Italy. The goal is to see how accurate the procedure is, how safe it is, and how quickly patients get a final diag…

This study enrolls 150 adults with suspected or confirmed pancreatic cancer who are scheduled for chemotherapy. Researchers will collect tumor samples via endoscopic ultrasound before and during treatment to analyze gene activity. They aim to understand how the cancer changes acr…

This study tests a remote education program to help people at higher risk for pancreatic cancer learn about genetic testing and a blood test that screens for multiple cancers. The program targets Black, Latino/a, and Medicaid-enrolled individuals in Massachusetts who may have had…

This observational study looks at how pancreatic cancer changes immune cells in the blood. Researchers will compare blood samples from 50 people with newly diagnosed, untreated pancreatic cancer to 50 age-matched people with a non-cancerous pancreatic condition. They aim to ident…

This observational study is investigating whether certain blood markers and gut microorganisms can help identify people with chronic pancreatitis who are at higher risk of developing pancreatic cancer. Researchers will compare healthy individuals, those with chronic pancreatitis,…

This study looks at whether a new blood test can find tiny bits of tumor DNA left behind after pancreatic cancer surgery. About 30 adults who had their cancer removed will give blood samples at three key times over six months. The goal is to see if this test can detect remaining …

This trial investigates whether a special type of MRI scan, called DCE-MRI, can better assess how well chemotherapy is working in people with borderline resectable pancreatic cancer. Participants will receive standard chemotherapy and undergo DCE-MRI scans along with regular imag…

The EXPAND study is a research project that will enroll 440 adults with and without pancreatic conditions to understand why type 2 diabetes varies so much from person to person. Researchers will collect data on metabolism, genetics, and pancreas health to identify distinct diabet…

This study will follow 800 people, including those with chronic pancreatitis, pancreatic cancer, and healthy volunteers, to learn why some pancreatitis patients later get pancreatic cancer. Participants give blood samples and health info; some may also provide tissue samples. Res…

This study is a registry that collects medical information and biological samples from up to 100,000 people with gastrointestinal cancers, such as pancreatic or colorectal cancer. No new treatments or drugs are given. The goal is to gather real-world data to help researchers answ…

This study aims to see if using a patient's genetic signature to choose chemotherapy can improve outcomes for people with borderline resectable pancreatic cancer. About 367 participants will receive standard chemotherapy, and researchers will track how long they live without majo…

This study aims to find biological markers in the blood, immune system, and gut microbiome that can help doctors choose the best treatment for people with advanced pancreatic cancer that cannot be removed by surgery. Researchers will collect blood and stool samples from 140 parti…

This study looks at whether a polygenic risk score—a measure based on many small genetic variations—can help predict who might develop pancreatic ductal adenocarcinoma (PDAC). Researchers will compare the genetic profiles of about 1,140 people with and without the disease. The go…

This study looks at whether draining a blocked bile duct before surgery for pancreatic cancer changes the tumor's behavior or patient survival. Researchers will review medical records of 90 patients who had their pancreatic tumor removed over 8 years. They will compare those who …

This study looks at whether doing broad gene testing early, instead of later, helps find more effective treatments for people with advanced pancreatic, liver, or triple-negative breast cancer. About 360 adults with poor-prognosis cancers will be randomly assigned to early or stan…

This observational study will enroll 185 people with metastatic pancreatic cancer to see if analyzing tumor genes and lab-grown organoids can predict which standard chemotherapy regimens work best. Researchers will compare predicted drug sensitivity to actual patient outcomes. Th…